Otros idiomas Simcere Pharmaceutical Group Limited

Acciones

2096

HK0000658531

Mercado cerrado - Hong Kong S.E. Otros sitios de cotización 10:08:20 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
5,3 ^HKD	+1,15 %		+2,91 %	-21,25 %

25/04	El beneficio de 'Simcere Pharmaceutical' baja un 23% en 2023	MT
10/04	El fármaco contra el cáncer de Simcere Pharmaceutical obtiene la designación de vía rápida de la FDA estadounidense	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Simcere Pharmaceutical’ Profit Down 23% in 2023	25/04
Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA	10/04
Simcere Pharmaceutical Group Limited Announces SIM0500 for Injection (a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody) Receives Fast Track Designation by the U.S. Food and Drug Administration	09/04
Simcere Pharmaceutical's 2023 Profit Falls, Misses Estimates; Shares Rise 3%	21/03
Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 15 July 2024	20/03
Simcere Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Simcere Pharmaceutical Group's Cancer Drug NDA Accepted by Chinese Regulator	18/03
Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China	15/03
Simcere Pharmaceutical Group's Cancer Drug Gets China Nod for Clinical Trials	13/03
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration	12/03
Simcere Pharmaceutical Group's New Anti-Cancer Drug Gets Clinical Trials Approval from the FDA	11/03
Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500	10/03
Simcere Pharmaceutical Group Limited Announces Findings of A Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in Jama	21/02
Simcere Pharma's Ischemic Stroke Treatment Results Published in US Neurology Journal	20/02
Simcere Pharmaceutical’s Profit to Fall Up to 27% in 2023	19/02
Simcere Pharmaceutical Expects Up to 26% Fall in 2023 Profit; Shares Slide 3%	19/02
Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	18/02
Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19	18/01
Simcere Pharma Unit's Shareholders Approve Order Collection Agreement	18/01
China Grants Clinical Trial Approval for Simcere Pharmaceutical's Anti-Tumor Medication	15/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Simcere Pharmaceutical Group Limited

Acciones

2096

HK0000658531

Otros idiomas

Filtros